The Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial.

backgroundCognitive behavioral therapy (CBT) is recommended as the first-line treatment for insomnia; however, few patients have access to it. A new class of Food and Drug Administration (FDA)-regulated digital CBT treatments has the potential to address this unmet need. These treatments are ordered or prescribed by health care providers and are fully automated, delivering CBT directly to patients without human coaches. This trial builds upon promising earlier digital cognitive behavioral therapy for insomnia (CBT-I) research by using a decentralized design to recruit a sample with greater representation of the US general population, including individuals from lower socioeconomic status groups who often face greater barriers to care.

objectiveThis decentralized trial evaluated the effectiveness of a fully automated digital CBT-I program (SleepioRx) for treating insomnia disorder compared with online sleep hygiene education (SHE) in a sample of participants recruited from across the United States.

methodsA decentralized, parallel-group randomized controlled trial was conducted between November 2022 and August 2023. Participants were recruited nationally from across the United States, and a total of 336 adults aged 22 and older, diagnosed with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) insomnia disorder via structured clinical interview, were allocated 1:1 to either digital CBT-I (SleepioRx) or online SHE. The primary end points were insomnia severity, assessed using the Insomnia Severity Index (ISI), and sleep diary measures of sleep onset latency (SOL) and wake after sleep onset (WASO) at 10 weeks, with follow-up assessments at 16 and 24 weeks postrandomization.

resultsCompared with SHE, SleepioRx showed statistically and clinically significant improvements on the ISI at posttreatment (10 weeks; Cohen d=0.60, P<.001), with effects sustained at follow-up (16 weeks; d=0.65, P<.001; and 24 weeks, d=0.77, P<.001). SleepioRx led to significant reductions in WASO at all time points (10 weeks, P=.003; 16 and 24 weeks, P<.001); however, effects on SOL were not statistically significant at an adjusted α (10 weeks, P=.01; 16 weeks, P=.07; 24 weeks, P=.27). SleepioRx participants had 2.5 times (odds ratio 2.52; P<.001, 99% CI 1.33-4.75) and 5.8 times (odds ratio 5.78; P<.001, 99% CI 2.11-15.84) greater odds of response and remission at week 10, respectively, with statistically and clinically significant differences in rates sustained at follow-up assessments (P<.001). SleepioRx also demonstrated sustained improvements in secondary sleep and broader mental health outcomes.

conclusionsThe results of this trial demonstrate the effectiveness of digital CBT-I (SleepioRx) for treating insomnia, with gains sustained at 6 months, and support the FDA authorization of SleepioRx for the treatment of insomnia disorder. These findings underscore the potential of a new class of FDA-authorized, fully automated digital treatments to provide first-line, guideline-recommended CBT at scale. Efforts should now focus on expanding access to these evidence-based treatments.

trial registrationClinicalTrials.gov NCT05541055; https://clinicaltrials.gov/ct2/show/NCT05541055.